Related Experiment Videos
Protease activated receptors in cardiovascular function and disease.
Junor A Barnes1, Shamjeet Singh, Aldrin V Gomes
1Biochemistry Unit, Faculty of Medical Sciences, University of the West Indies, St. Augustine, Trinidad, West Indies. jbarnes@carib-link.net
Molecular and Cellular Biochemistry
|November 5, 2004
Summary
Protease-activated receptors (PARs) are key G protein-coupled receptors involved in cardiovascular function. This review explores their roles in cardiovascular health and disease, highlighting recent findings in molecular signaling.
Area of Science:
- Cardiovascular Biology
- Molecular Signaling
- G protein-coupled receptors
Background:
- Protease-activated receptors (PARs) are a novel class of seven transmembrane G protein-coupled receptors.
- PARs are activated by serine proteases (e.g., thrombin, trypsin) through proteolytic cleavage, forming a tethered ligand.
- Four PAR subtypes (PAR-1, PAR-2, PAR-3, PAR-4) have been identified, with ongoing research into their specific roles.
Purpose of the Study:
- To review the current understanding of PARs' involvement in cardiovascular function.
- To explore the physiological and pathological roles of PARs in cardiovascular disease.
- To summarize recent advancements in PAR research, particularly in molecular signaling.
Main Methods:
- Review of recent scientific literature on PARs.
- Analysis of studies utilizing animal models, primarily transgenic mice.
- Examination of research on synthetic tethered ligand domains.
Main Results:
- PAR-1, PAR-2, and PAR-4 are implicated in vascular development, apoptosis, and tissue remodeling.
- PARs mediate intracellular signaling pathways triggered by extracellular proteolysis.
- Animal models and synthetic ligands have significantly advanced knowledge of PAR function.
Conclusions:
- PARs play critical roles in cardiovascular physiology and pathology.
- Further research is needed to fully elucidate the discrete functions of each PAR subtype.
- Understanding PAR signaling is crucial for developing novel cardiovascular therapies.